Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Trial Profile

Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 May 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
    • 14 Apr 2013 Status changed from not yet recruiting to recruiting as reported by Mayo Clinic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top